

DAFTAR PUSTAKA

- Adamichou, C., & Bertsias, G., 2017, Flares in Systemic Lupus Erythematosus: Diagnosis, Risk Factors and Preventive Strategies, *Mediterr J Rheumatol*, 28(1):4-12, <https://doi.org/10.31138/mjr.28.1.4>
- American College of Rheumatology, 2023, *Mycophenolate Mofetil (CellCept) and Mycophenolate Sodium (Myfortic)*, tersedia pada: <https://rheumatology.org/patients/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic>
- Ameer, M. A., Chaudhry, H., Mushtaq, J., Khan, O. S., Babar, M., Hashim, T., Zeb, S., Tariq, M. A., Patlolla, S. R., Ali, J., Hashim, S. N., Hashim, S., 2022, An Overview of Systemic Lupus Erythematosus (SLE) Pathogenesis, Classification, and Management, *Cureus*, 15;14(10):e30330. <https://doi.org/10.7759/cureus.30330>
- Amissah-Arthur, M. B., Gordon, C., 2010, Contemporary Treatment of Systemic Lupus Erythematosus: an update for clinicians, *Ther Adv Chronic Dis*, (4): 163 – 75. <https://doi.org/10.1177/2040622310380100>
- Angum, F., Khan, T., Kaler, J., Siddiqui, L., Hussain, A., 2020, The Prevalence of Autoimmune Disorders in Women: A Narrative Review, *Cureus*, 12(5). <https://doi.org/10.7759/cureus.8094>
- Autoimmune Association, 2023, *About Autoimmunity*, tersedia pada: <https://autoimmune.org/resource-center/about-autoimmunity/>
- Bagga, A., 2008, Revised guidelines for management of steroid-sensitive nephrotic syndrome, *Indian J Nephrol*, 18(1):31 – 39. <https://doi.org/10.4103/0971-4065.41289>
- Bhat, R., Tonutti, A., Timilsina, S., Selmi, C., Gershwin, M. E., 2023, Perspective on Mycophenolate Mofetil in the Management of Autoimmunity, *Clinical Reviews in Allergy & Immunology*, 65: 86 – 100.
- Binu, A., Kumar, S. S., Padma, U. D., Madhu, K., 2022, Pathophysiological basis in the management of myasthenia gravis: a mini review, *Inflammopharmacol*, 30, 61-71. <https://doi.org/10.1007/s10787-021-00905-9>
- BPOM, 2012, *Pedoman Monitoring Efek Samping Obat (MESO) Bagi Tenaga Kesehatan*, BPOM RI, Jakarta.
- Bullock, J., Rizvi, S. A. A., Saleh, A. M., Ahmed, S. S., Do, D. P., Ansari, R. A., Ahmed, J., 2019, Rheumatoid Arthritis: A Brief Overview of the Treatment, *Medical Principles and Practice*, 27(6), 501 – 507. <https://doi.org/10.1159/000493390>
- CADTH, 2020, *Clinical Review Report Eculizumab (Soliris)*, CADTH Common Drug Review.
- Cojocaru, M., Cojocaru, I. M., Silosi, I., Vrabie, C. D., 2011, Manifestations of Systemic Lupus Erythematosus, *Maedica (Bucur)*, 6(4): 330 – 336.
- Conti-Fine, B. M., Milani, M., Kaminski, H. J., 2006, Myasthenia gravis: past, present, and future, *J Clin Invest*, 116(11): 2843 – 2854. <https://doi.org/10.1172/JCI29894>

- Deshmukh, R., 2023, Rheumatoid arthritis: Pathophysiology, current therapeutic strategies and recent advances in targeted drug delivery system, *Materials Today Communications*, 35. <https://doi.org/10.1016/j.mtcomm.2023.105877>
- Dima, A., Jurcut, C., Chasset, F., Felten, R., Arnaud, L., 2022, Hydroxychloroquine in Systemic Lupus Erythematosus: Overview of Current Knowledge, *Ther Adv Musculoskelet Dis*, 14:1759720X211073001. <https://doi.org/10.1177/1759720X211073001>
- El-Shebiny, E. M., Zahran, E. S., Shoeib, S. A., Habib, E. S., 2021, Bridging autoinflammatory and autoimmune diseases, *The Egyptian Journal of Internal Medicine*, 33(11). <https://doi.org/10.1186/s43162-021-00040-5>
- Ershadinia, N., Mortazavinia N., Babaniamansour, S., Najafi-Nesheli, M., Babaniamansour, P., Aliniagerdroudbari, E., 2020, The prevalence of autoimmune diseases in patients with multiple sclerosis: A cross-sectional study in Qom, Iran, in 2018, *Current Journal of Neurology*, 19(3):98–102. <https://doi.org/10.18502/cjn.v19i3.5421>
- Fatoye, F., Gebrye, T., Mbada, C., 2022, Global and Regional Prevalence and Incidence of Systemic Lupus Erythematosus in Low-and-Middle Income countries: a Systemic Review and Meta-Analysis, *Rheumatol Int*, 42: 2097 – 2107. <https://doi.org/10.1007/s00296-022-05183-4>
- Floris, A., Chessa, E., Sebastiani, G. D., Prevete, I., Iannone, F., Coladonato, L., Govoni, M., Bortoluzzi, A., Mosca, M., Tani, C., Doria, A., Iaccarino, L., Franceschini, F., Fredi, M., Conti, F., Spinelli, F. R., Bellisai, F., D'Alessandro, R., Zanetti, A., Carrara, G., Scirè, C. A., Cauli, A., Piga, M., 2022, Glucocorticoid Tapering and Associated Outcome in Patients With Newly Diagnosed Systemic Lupus Erythematosus: The Real-World GULP Prospective Observational Study, *RMD Open*, 8(2):e002701. <https://doi.org/10.1136/rmdopen-2022-002701>
- Furuto, Y., Kawamura, M., Namikawa, A., Takahashi, H., Shibuya, Y., 2020, Efficacy of High-Dose Mycophenolate Mofetil in Multitarget Therapy for Lupus Nephritis: Two Consecutive Case Reports, *Cureus*, 12(1):e6834. <https://doi.org/10.7759/cureus.6834>
- Grossman, J. M., 2009, Lupus arthritis, *Best Pract Res Clin Rheumatol*, 23(4): 495 – 506. <https://doi.org/10.1016/j.berh.2009.04.003>
- Haneishi, Y., Furuya, Y., Hasegawa, M., Picarelli, A., Rossi, M., Miyamoto, J., 2023, Inflammatory Bowel Diseases and Gut Microbiota, *International Journal of Molecular Sciences*, 24(4):3817. <https://doi.org/10.3390/ijms24043817>
- Hegar, B., Ananta, Y., Rini, D., 2007, Inflammatory bowel disease in Indonesian children, *Paediatrica Indonesiana*, 47(6).
- Heeter, Z., 2012, Current Therapies for Lupus Nephritis, *US Pharm*, 37(6).
- Ikatan Dokter Anak Indonesia (IDAI), 2012, *Konsensus Tata Laksana Sindrom Nefrotik Idiopatik Pada Anak*, Badan Penerbit Ikatan Dokter Anak Indonesia, Jakarta.
- Jaryal, A., Vikrant, S., 2017, Current Status of Lupus Nephritis, *Indian J Med Res*, 145(2): 167 – 178. https://doi.org/10.4103/ijmr.IJMR_163_16

- Jehangir, A., Shaikh, B., Hunt, J., Spiegel, A., 2016, Severe Enteropathy From Mycophenolate Mofetil, *ACG Case Report Journal*, 3(2): 101 – 103. <https://doi.org/10.14309/crj.2016.13>
- Jones, R. B., Walsh, M., Chaudhry, A. N., Smith, K. G. C., Jayne, D. R. W., 2014, Randomized Trial of Enteric-Coated Mycophenolate Sodium versus Mycophenolate Mofetil in Multi-System Autoimmune Disease, *Clinical Kidney Journal*, 7(6): 562 – 568. <https://doi.org/10.1093/ckj/sfu096>
- Jordan, N. & D'Cruz, D., 2016, Current and Emerging Treatment Options in The Management of Lupus, *ImmunoTargets and Therapy*, 5: 9 – 20. <https://doi.org/10.2147/ITT.S40675>
- Justiz Vaillant, A. A., Goyal, A., Varacallo, M., 2023, *Systemic Lupus Erythematosus*. In: *StatPearls*, StatPearls Publishing, Treasure Island (FL).
- Kakati, S., Barman, B., Ahmed, S. U., Hussain, M., 2017, Neurological Manifestations in Systemic Lupus Erythematosus: A Single Centre Study from North East India, *J Clin Diagn Res*, 11(1):OC05-OC09. <https://doi.org/10.7860/JCDR/2017/23773.9280>
- Kariniemi, S., Rantalaiho, V., Virta, L. J., Puolakka, K., Sokka-Isler, T., Elfving, P., 2021, Multimorbidity among incident Finnish systemic lupus erythematosus patients during 2000-2017, *Lupus*, 30(1):165 – 171. <https://doi.org/10.1177/0961203320967102>
- Kemkes RI, 2018, *Hari Lupus Sedunia 2018: Memahami Program Deteksi Dini Penyakit Lupus Eritematosus Sistemik (LES)*, Direktorat Jenderal Pencegahan dan Pengendalian Penyakit, tersedia pada: <http://p2p.kemkes.go.id/hari-lupus-sedunia-2018-memahami-program-deteksi-dini-penyakit-lupus-eritematosus-sistemik-les/>
- Kementerian Kesehatan RI, 2022, *Mengenal Penyakit Lupus/SLE*, Direktorat Jenderal Pelayanan Kesehatan, tersedia pada: https://yankes.kemkes.go.id/view_artikel/1423/mengenal-penyakit-lupussle#:~:text=Kelompok%20umur%20yang%20sering%20terkena,kont rasepsi%20oral%20yang%20mengandung%20estrogen
- Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group, 2012, KDIGO Clinical Practice Guideline for Glomerulonephritis, *Kidney Int, Suppl*, 2: 139 – 274.
- Kurup, S. & Pozun, A., 2023, *Biochemistry, Autoimmunity*. In: *StatPearls*, StatPearls Publishing, Treasure Island (FL).
- Lee, J. C. & Smith, K. G. C., 2014, Prognosis in autoimmune and infectious disease: new insights from genetics, *Clinical & Translational Immunology*, 3(5): e15. <https://doi.org/10.1038/cti.2014.8>
- Lexicomp, 2023, Mycophenolic Acid [Mycophenolate] (Lexi-Drugs Multinational), *Wolters Kluwer*, tersedia pada: <https://online.lexi.com/>
- Li, L., Xiong, W-C., Mei, L., 2018, *Neuromuscular Junction Formation, Aging, and Disorders*. In *Annual Reviews of Physiology*, 80: 159 – 188. <https://doi.org/10.1146/annurev-physiol-022516-034255>
- Liu, J. L., Pineau, C. A., Grenier, L. P., Vinet, E., Kalache, F., Lukusa, L., Bernatsky, S., 2021, Treatment Patterns and Control of Hypertension in Systemic

- Lupus Erythematosus (SLE): a cross-sectional study, *BMJ Open*, 11(11):e048384. <https://doi.org/10.1136/bmjopen-2020-048384>
- Machado-Alba, J. E., Machado-Duque, M. E., Gaviria-Mendoza, A., Duarte-Rey, C., González-Rangel, A., 2023, Clinical Characterization of a Cohort of Patients Treated for Systemic Lupus Erythematosus in Colombia: A retrospective study, *PLoS One*, 18(5):e0285889. <https://doi.org/10.1371/journal.pone.0285889>
- McDowell, C., Farooq, U., Haseeb, M., 2023, *Inflammatoru Bowel Disease*. In: *StatPearls*, StatPearls Publishing, Treasure Island (FL).
- McKeon, K. P., Jiang, S. H., 2020, Treatment of Systemic Lupus Erythematosus, *Aust Prescr*, 43(3):85 – 90. <https://doi.org/10.18773/austprescr.2020.022>
- Mebrahtu, T. F., Morgan, A. W., West, R. M., Stewart, P. M., Pujades-Rodriguez, M., 2020, Oral Glucocorticoids and Incidence of Hypertension in People with Chronic Inflammatory Diseases: a population-based cohort study, *CMAJ*, 192(12):E295-E301. <https://doi.org/10.1503/cmaj>
- Musa, R., Brent, L. H., Qurie, A., 2023, *Lupus Nephritis*, In: *StatPearls*, StatPearls Publishing, Treasure Island (FL).
- Mydlarski, P. R., 2005, Mycophenolate mofetil: a dermatologic perspective, *Skin Therapy Lett*, 10(3): 1 – 6.
- Nimesh, S., Ahmad, M. I., Dhama, S., Kumar, P., Akram, M., Hasaroeih, N. E. N., 2021, Systemic Lupus Erythematosus Disease: An Overview of the Clinical Approach to Pathogenesis, Diagnosis, and Treatment, *Borneo Journal of Pharmacy*, 4(2), 91 – 98. <https://doi.org/10.33084/bjop.v4i2.1950>
- Panagopoulos, P. K., Lambrou, G. I., 2018, Bone erosions in rheumatoid arthritis: recent developments in pathogenesis and therapeutic implications, *Journal of Musculoskeletal and Neuronal Interactions*, 18(3), 304 – 319.
- Park, H., 2011, The Emergence of Mycophenolate Mofetilin Dermatology: From Its Roots in the World of Organ Transplantation to its Versatile Role in the Dermatology Treatment Room, *The Journal and Aesthetic Dermatology*, 4(1): 18 – 27.
- Pawlak-Bus, K. & Leszczynski, P., 2022 Systemic Lupus Erythematosus Remission in Clinical Practice. Message for Polish Rheumatologist, *Reumatologia*, 60(2): 125 – 132. <https://doi.org/10.5114/reum.2022.115667>
- Perhimpunan Reumatologi Indonesia, 2019, *Diagnosis dan Pengelolaan Lupus Eritematosus Sistemik*, Perhimpunan Reumatologi Indonesia, Jakarta.
- Perhimpunan Reumatologi Indonesia, 2021, *Diagnosis dan Pengelolaan ARTRITIS REUMATOID*, Perhimpunan Reumatologi Indonesia, Jakarta.
- Pisetsky, D. S., 2023, Pathogenesis of autoimmune disease, *Nature Reviews Nephrology*, 19: 509 – 524. <https://doi.org/10.1038/s41581-023-00720-1>
- Pratiwi, A., 2023, Kejadian Tidak Diinginkan Penggunaan Kortikosteroid pada Terapi Penyakit Autoimun di Poli Anak RSUP Dr. Sardjito Yogyakarta, *Skripsi*, Universitas Gadjah Mada, Yogyakarta.
- Ramirez Sepulveda, J. I., Bolin, K., Mofors, J., Leonard, D., Svenungsson, E., Jonsen, A., Bengtsson, C., Nordmark, G., Dahlqvist, S. R., Bengtsson, A. A., Ronnblom, L., Sjowall, C., Gunnarsson, I., Wahren-Herlenius, M. W., Cosortium, T. D., 2019, Sex Difference in Clinical Presentation of Systemic

- Lupus Erythematosus, *Biol Sex Differ* 10, 60.
<https://doi.org/10.1186/s13293-019-0274-2>
- Rheault, M., 2016, Nephrotic Syndrome: Updates and Approaches to Treatment, *Curr Treat Option Peds* 2, 94 – 103. <https://doi.org/10.1007/s40746-016-0044-x>
- Rosas, J. M., Touma, Z., 2015, Proteinuria: Assesment and Utility in Lupus Nephritis, *Journal of Orthopedic Research & Physiotherapy*, 2:027, <https://doi.org/10.24966/ORP-2052/100027>
- Smolen, J. S., Aletaha, D., McInnes, I. B., 2016, Rheumatoid arthritis, *The Lancet*, 388: 2023 – 2038. [https://doi.org/10.1016/S0140-6736\(16\)30173-8](https://doi.org/10.1016/S0140-6736(16)30173-8)
- Suresh, A. B. & Asuncion, R. M. D., 2023, *Myasthenia Gravis*. In: *StatPearls*, StatPearls Publishing, Treasure Island (FL).
- Surjushe, A. & Saple, D. G., 2008, Mycophenolate mofetil, *Indian Journal of Dermatology Venereology and Leprology*, 74: 180 – 184. <https://doi.org/10.4103/0378-6323.39725>
- Tapia, C., & Bashir, K., 2023, *Nephrotic Syndrome*. In: *StatPearls*, StatPearls Publishing, Treasure Island (FL).
- Tugasworo, D., 2018, *Myasthenia Gravis Diagnosis dan Tata Laksana*, Undip Press, Semarang.
- Tyson, R. J., Park, C. C., Powell, J. R., Patterson, J. H. Weiner, D., Watkins, P. B., Gonzalez, D., 2020, Precision Dosing Priority Criteria: Drug, Disease, and Patient Population Variables, *Frontiers in Pharmacology*, 11: 420. <https://doi.org/10.3389/fphar.2020.00420>
- Verschuuren, J. J. G. M., Huijbers, M. G., Plomp, J. J., Niks, E. H., Molenaar, P. C., Martinez-Martinez, P., Gomez, A. M., Baets, M. H. D., Losen, M., 2013, Autoimmunity Reviews: Pathophysiology of myasthenia gravis with antibodies to the acetylcholine receptor, muscle-specific kinase and low-density lipoprotein receptor-related protein 4, *Elsevier*, 12(9): 918 – 923. <http://dx.doi.org/10.1016/j.autrev.2013.03.001>
- Wang, L., Wang, F.-S., Gershwin, M. E., 2015, Human autoimmune diseases: a comprehensive update. *Journal of Internal Medicine*, 278(4), 369–395. <https://doi.org/10.1111/joim.12395>